Voyager Therapeutics Inc. (NASDAQ:VYGR)’s share price was up 4.7% during mid-day trading on Friday . The stock traded as high as $12.90 and last traded at $12.49, with a volume of 132,291 shares changing hands. The stock had previously closed at $11.93.

Several equities analysts have issued reports on VYGR shares. Cowen and Company reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Piper Jaffray Cos. reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Saturday, April 30th. Stifel Nicolaus started coverage on shares of Voyager Therapeutics in a research note on Thursday. They issued a “buy” rating and a $33.00 price objective on the stock. Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 7th. Finally, Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Voyager Therapeutics in a research note on Sunday, March 20th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Voyager Therapeutics currently has an average rating of “Buy” and a consensus target price of $30.25.

The firm has a 50-day moving average price of $12.81 and a 200-day moving average price of $12.09. The company’s market cap is $333.83 million.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Thursday, May 12th. The company reported $0.29 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.67. Equities analysts predict that Voyager Therapeutics Inc. will post ($1.54) earnings per share for the current year.

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.